Knowledge of drug MOA is critical for novel therapeutics but extremely challenging. Metabolon’s technology is uniquely positioned to accelerate MOA, identify biomarkers, further personalized medicine and tailor therapy approaches.

GeminX’s data suggested putative MOA was in question and wanted clarity. The leading hypothesis implied that GMX1778 caused tumor cell death via inhibition of the I B kinase enzyme complex and decreased NF- B activity.